The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy

[1]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Yong Q. Chen,et al.  Metabolic Alterations Induced by Kudingcha Lead to Cancer Cell Apoptosis and Metastasis Inhibition , 2020, Nutrition and cancer.

[3]  T. Beißbarth,et al.  Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial , 2019, International journal of cancer.

[4]  Chang-ming Huang,et al.  The predictive value of the preoperative C-reactive protein–albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data , 2019, Gastric Cancer.

[5]  M. Giovagnoli,et al.  Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment , 2019, AntiCancer Research.

[6]  Huimian Xu,et al.  The Impact of Preoperative Underweight Status on Postoperative Complication and Survival Outcome of Gastric Cancer Patients: A Systematic Review and Meta-analysis , 2018, Nutrition and cancer.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  A. Xu,et al.  Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study. , 2018, International journal of surgery.

[9]  Chang-ming Huang,et al.  Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer , 2018, Gastric Cancer.

[10]  S. Parsons,et al.  Anaemia and its effects on tumour regression grade and survival following chemotherapy in adenocarcinoma of the oesophagus. , 2018, Journal of gastrointestinal oncology.

[11]  S. Gandini,et al.  Carcinogenicity of High Consumption of Meat and Lung Cancer Risk Among Non-Smokers: A Comprehensive Meta-Analysis , 2018, Nutrition and cancer.

[12]  S. Cai,et al.  Prognostic value of systemic immune-inflammation index in patients with gastric cancer , 2017, Chinese journal of cancer.

[13]  Yingwei Xue,et al.  Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy , 2017, OncoTargets and therapy.

[14]  Xiaosun Liu,et al.  The prognostic value of neutrophil–lymphocyte ratio is superior to derived neutrophil–lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up , 2017, OncoTargets and therapy.

[15]  Yingwei Xue,et al.  Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy , 2017, OncoTargets and therapy.

[16]  Guoli Li,et al.  Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[17]  Masahiro Ito,et al.  A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy , 2017, Surgery Today.

[18]  T. Sano.  Gastric cancer: Asia and the world , 2017, Gastric Cancer.

[19]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology , 2016 .

[20]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[21]  Sarah T. Jewell,et al.  The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review , 2016, Supportive Care in Cancer.

[22]  Jian Li,et al.  Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[23]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Nagawa,et al.  Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer , 2010, Radiation oncology.

[25]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[27]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of surgery.

[28]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  Jeffrey E. Gershenwald,et al.  Organization of the AJCC Cancer Staging Manual , 2016 .

[30]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.